Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Research letter

Physicians' perceptions of the benefits and risks of warfarin for patients with nonvalvular atrial fibrillation

Tammy J. Bungard, William A. Ghali, Finlay A. McAlister, Alastair M. Buchan, Andrew J. Cave, Peter G. Hamilton, L. Brent Mitchell, Ashfaq Shuaib, Koon K. Teo and Ross T. Tsuyuki
CMAJ August 07, 2001 165 (3) 301-302;
Tammy J. Bungard
Dr. Bungard is with the Division of Cardiology, University of Alberta, Edmonton, Alta. Dr. Ghali is with the Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alta. Dr. McAlister is with the Division of General Internal Medicine and the EPICORE Centre, Division of Cardiology, University of Alberta, Edmonton, Alta. Dr. Buchan is with the Department of Clinical Neurosciences, University of Calgary, Calgary, Alta. Dr. Cave is with the Department of Family Medicine, University of Alberta, Edmonton, Alta. Dr. Hamilton is with the Department of General Internal Medicine, University of Alberta, Edmonton, Alta. Dr. Mitchell is with the Division of Cardiology, University of Calgary, Calgary, Alta. Dr. Shuaib is with the Division of Neurology, University of Alberta, Edmonton, Alta. When the study was being carried out, Dr. Teo was with the Division of Cardiology, University of Alberta, Edmonton, Alta., but is now with the Department of Medicine, McMaster University, Hamilton, Ont. Dr. Tsuyuki is with the EPICORE Centre, Division of Cardiology, University of Alberta, Edmonton, Alta.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William A. Ghali
Dr. Bungard is with the Division of Cardiology, University of Alberta, Edmonton, Alta. Dr. Ghali is with the Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alta. Dr. McAlister is with the Division of General Internal Medicine and the EPICORE Centre, Division of Cardiology, University of Alberta, Edmonton, Alta. Dr. Buchan is with the Department of Clinical Neurosciences, University of Calgary, Calgary, Alta. Dr. Cave is with the Department of Family Medicine, University of Alberta, Edmonton, Alta. Dr. Hamilton is with the Department of General Internal Medicine, University of Alberta, Edmonton, Alta. Dr. Mitchell is with the Division of Cardiology, University of Calgary, Calgary, Alta. Dr. Shuaib is with the Division of Neurology, University of Alberta, Edmonton, Alta. When the study was being carried out, Dr. Teo was with the Division of Cardiology, University of Alberta, Edmonton, Alta., but is now with the Department of Medicine, McMaster University, Hamilton, Ont. Dr. Tsuyuki is with the EPICORE Centre, Division of Cardiology, University of Alberta, Edmonton, Alta.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Finlay A. McAlister
Dr. Bungard is with the Division of Cardiology, University of Alberta, Edmonton, Alta. Dr. Ghali is with the Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alta. Dr. McAlister is with the Division of General Internal Medicine and the EPICORE Centre, Division of Cardiology, University of Alberta, Edmonton, Alta. Dr. Buchan is with the Department of Clinical Neurosciences, University of Calgary, Calgary, Alta. Dr. Cave is with the Department of Family Medicine, University of Alberta, Edmonton, Alta. Dr. Hamilton is with the Department of General Internal Medicine, University of Alberta, Edmonton, Alta. Dr. Mitchell is with the Division of Cardiology, University of Calgary, Calgary, Alta. Dr. Shuaib is with the Division of Neurology, University of Alberta, Edmonton, Alta. When the study was being carried out, Dr. Teo was with the Division of Cardiology, University of Alberta, Edmonton, Alta., but is now with the Department of Medicine, McMaster University, Hamilton, Ont. Dr. Tsuyuki is with the EPICORE Centre, Division of Cardiology, University of Alberta, Edmonton, Alta.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alastair M. Buchan
Dr. Bungard is with the Division of Cardiology, University of Alberta, Edmonton, Alta. Dr. Ghali is with the Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alta. Dr. McAlister is with the Division of General Internal Medicine and the EPICORE Centre, Division of Cardiology, University of Alberta, Edmonton, Alta. Dr. Buchan is with the Department of Clinical Neurosciences, University of Calgary, Calgary, Alta. Dr. Cave is with the Department of Family Medicine, University of Alberta, Edmonton, Alta. Dr. Hamilton is with the Department of General Internal Medicine, University of Alberta, Edmonton, Alta. Dr. Mitchell is with the Division of Cardiology, University of Calgary, Calgary, Alta. Dr. Shuaib is with the Division of Neurology, University of Alberta, Edmonton, Alta. When the study was being carried out, Dr. Teo was with the Division of Cardiology, University of Alberta, Edmonton, Alta., but is now with the Department of Medicine, McMaster University, Hamilton, Ont. Dr. Tsuyuki is with the EPICORE Centre, Division of Cardiology, University of Alberta, Edmonton, Alta.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew J. Cave
Dr. Bungard is with the Division of Cardiology, University of Alberta, Edmonton, Alta. Dr. Ghali is with the Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alta. Dr. McAlister is with the Division of General Internal Medicine and the EPICORE Centre, Division of Cardiology, University of Alberta, Edmonton, Alta. Dr. Buchan is with the Department of Clinical Neurosciences, University of Calgary, Calgary, Alta. Dr. Cave is with the Department of Family Medicine, University of Alberta, Edmonton, Alta. Dr. Hamilton is with the Department of General Internal Medicine, University of Alberta, Edmonton, Alta. Dr. Mitchell is with the Division of Cardiology, University of Calgary, Calgary, Alta. Dr. Shuaib is with the Division of Neurology, University of Alberta, Edmonton, Alta. When the study was being carried out, Dr. Teo was with the Division of Cardiology, University of Alberta, Edmonton, Alta., but is now with the Department of Medicine, McMaster University, Hamilton, Ont. Dr. Tsuyuki is with the EPICORE Centre, Division of Cardiology, University of Alberta, Edmonton, Alta.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter G. Hamilton
Dr. Bungard is with the Division of Cardiology, University of Alberta, Edmonton, Alta. Dr. Ghali is with the Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alta. Dr. McAlister is with the Division of General Internal Medicine and the EPICORE Centre, Division of Cardiology, University of Alberta, Edmonton, Alta. Dr. Buchan is with the Department of Clinical Neurosciences, University of Calgary, Calgary, Alta. Dr. Cave is with the Department of Family Medicine, University of Alberta, Edmonton, Alta. Dr. Hamilton is with the Department of General Internal Medicine, University of Alberta, Edmonton, Alta. Dr. Mitchell is with the Division of Cardiology, University of Calgary, Calgary, Alta. Dr. Shuaib is with the Division of Neurology, University of Alberta, Edmonton, Alta. When the study was being carried out, Dr. Teo was with the Division of Cardiology, University of Alberta, Edmonton, Alta., but is now with the Department of Medicine, McMaster University, Hamilton, Ont. Dr. Tsuyuki is with the EPICORE Centre, Division of Cardiology, University of Alberta, Edmonton, Alta.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L. Brent Mitchell
Dr. Bungard is with the Division of Cardiology, University of Alberta, Edmonton, Alta. Dr. Ghali is with the Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alta. Dr. McAlister is with the Division of General Internal Medicine and the EPICORE Centre, Division of Cardiology, University of Alberta, Edmonton, Alta. Dr. Buchan is with the Department of Clinical Neurosciences, University of Calgary, Calgary, Alta. Dr. Cave is with the Department of Family Medicine, University of Alberta, Edmonton, Alta. Dr. Hamilton is with the Department of General Internal Medicine, University of Alberta, Edmonton, Alta. Dr. Mitchell is with the Division of Cardiology, University of Calgary, Calgary, Alta. Dr. Shuaib is with the Division of Neurology, University of Alberta, Edmonton, Alta. When the study was being carried out, Dr. Teo was with the Division of Cardiology, University of Alberta, Edmonton, Alta., but is now with the Department of Medicine, McMaster University, Hamilton, Ont. Dr. Tsuyuki is with the EPICORE Centre, Division of Cardiology, University of Alberta, Edmonton, Alta.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ashfaq Shuaib
Dr. Bungard is with the Division of Cardiology, University of Alberta, Edmonton, Alta. Dr. Ghali is with the Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alta. Dr. McAlister is with the Division of General Internal Medicine and the EPICORE Centre, Division of Cardiology, University of Alberta, Edmonton, Alta. Dr. Buchan is with the Department of Clinical Neurosciences, University of Calgary, Calgary, Alta. Dr. Cave is with the Department of Family Medicine, University of Alberta, Edmonton, Alta. Dr. Hamilton is with the Department of General Internal Medicine, University of Alberta, Edmonton, Alta. Dr. Mitchell is with the Division of Cardiology, University of Calgary, Calgary, Alta. Dr. Shuaib is with the Division of Neurology, University of Alberta, Edmonton, Alta. When the study was being carried out, Dr. Teo was with the Division of Cardiology, University of Alberta, Edmonton, Alta., but is now with the Department of Medicine, McMaster University, Hamilton, Ont. Dr. Tsuyuki is with the EPICORE Centre, Division of Cardiology, University of Alberta, Edmonton, Alta.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Koon K. Teo
Dr. Bungard is with the Division of Cardiology, University of Alberta, Edmonton, Alta. Dr. Ghali is with the Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alta. Dr. McAlister is with the Division of General Internal Medicine and the EPICORE Centre, Division of Cardiology, University of Alberta, Edmonton, Alta. Dr. Buchan is with the Department of Clinical Neurosciences, University of Calgary, Calgary, Alta. Dr. Cave is with the Department of Family Medicine, University of Alberta, Edmonton, Alta. Dr. Hamilton is with the Department of General Internal Medicine, University of Alberta, Edmonton, Alta. Dr. Mitchell is with the Division of Cardiology, University of Calgary, Calgary, Alta. Dr. Shuaib is with the Division of Neurology, University of Alberta, Edmonton, Alta. When the study was being carried out, Dr. Teo was with the Division of Cardiology, University of Alberta, Edmonton, Alta., but is now with the Department of Medicine, McMaster University, Hamilton, Ont. Dr. Tsuyuki is with the EPICORE Centre, Division of Cardiology, University of Alberta, Edmonton, Alta.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ross T. Tsuyuki
Dr. Bungard is with the Division of Cardiology, University of Alberta, Edmonton, Alta. Dr. Ghali is with the Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alta. Dr. McAlister is with the Division of General Internal Medicine and the EPICORE Centre, Division of Cardiology, University of Alberta, Edmonton, Alta. Dr. Buchan is with the Department of Clinical Neurosciences, University of Calgary, Calgary, Alta. Dr. Cave is with the Department of Family Medicine, University of Alberta, Edmonton, Alta. Dr. Hamilton is with the Department of General Internal Medicine, University of Alberta, Edmonton, Alta. Dr. Mitchell is with the Division of Cardiology, University of Calgary, Calgary, Alta. Dr. Shuaib is with the Division of Neurology, University of Alberta, Edmonton, Alta. When the study was being carried out, Dr. Teo was with the Division of Cardiology, University of Alberta, Edmonton, Alta., but is now with the Department of Medicine, McMaster University, Hamilton, Ont. Dr. Tsuyuki is with the EPICORE Centre, Division of Cardiology, University of Alberta, Edmonton, Alta.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

Numerous randomized controlled trials (RCTs) have conclusively demonstrated that long-term anticoagulation in patients with nonvalvular atrial fibrillation (NVAF) can reduce the risk of stroke by approximately 68% per year, with a low annual risk of major hemorrhage (1.3%).1 Despite these impressive results, several studies have shown that the use of warfarin in the “real world” for the prevention of ischemic stroke is suboptimal, with only 15%–44% of patients with atrial fibrillation who had no contraindication to the therapy actually receiving warfarin.2 The reasons for this discrepancy between the RCT evidence and clinical practice patterns are unknown.

To test the hypothesis that physicians may underestimate the benefits and overestimate the risks of anticoagulation therapy, we conducted a survey of all cardiologists (n = 58), neurologists (n = 34) and general internists (n = 130) and a random sample of family physicians (n = 243) within the province of Alberta (first mailing in December 1998 and third mailing in June 1999). The response rate was 49% for family physicians, 73% for specialists and 60% overall.

The survey assessed knowledge by presenting a hypothetical patient with NVAF typical of those enrolled in the RCTs. Physicians were then asked to estimate the relative risk reduction (RRR) for stroke (if the patient was taking warfarin or if the patient was taking ASA) and the absolute risk of a major hemorrhage (if the patient was taking warfarin) on a continuum ranging from 0% to 100%, expressed as annual rates.

Respondents underestimated the RRR with warfarin therapy (mean estimate of 53%) compared with that shown in the RCTs (68%) and overestimated the risk of major hemorrhage (10% absolute annual risk v. 1% respectively) (Table 1). In contrast, the mean RRR of ASA was estimated to be higher (27%) than that documented in RCTs (21%).3 Interestingly, family physicians estimated ASA to be significantly more efficacious and the risk of major hemorrhage with warfarin to be significantly higher than the specialists had estimated. Because warfarin therapy is typically monitored by family physicians, these misconceptions may affect a large absolute number of patients.

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 1.

The estimation of a higher risk of hemorrhage with warfarin by family physicians (compared with specialists) has been reported previously.4,5 This may be due to several factors. First, family physicians monitor warfarin therapy on a long-term basis and, therefore, they are more likely to witness adverse outcomes in clinical practice. As such, there may be a natural tendency to remember these sequelae selectively when the therapeutic benefits are intangible (namely, the avoidance of a thromboembolic event). Second, the higher rates of hemorrhage reported by family physicians may reflect the reality of anticoagulant control outside RCTs. Specialists commonly recommend or initiate warfarin therapy based on clinical guidelines and RCTs, or both, but the long-term follow-up is left to the family physician. Patients outside RCTs typically have more concomitant disease and take more drugs, making it more difficult to provide them with appropriate anticoagulation therapy.

Whatever is causing these estimates, it is clear that considerable variability in the evidence for efficacy or hemorrhage with warfarin for patients with NVAF was reported by the survey respondents, as is reflected in the wide standard deviations. This suggests the need for further clinician education and strategies to quantify explicitly individual patients' risks and the potential benefits of warfarin and ASA.

Acknowledgments

At the time of writing, Dr. Bungard was supported by the Alberta Heritage Foundation for Medical Research. Drs. Ghali, Buchan, McAlister and Teo are supported by the Alberta Heritage Foundation for Medical Research. Dr. Ghali is also supported by a Government of Canada Research Chair. This study was supported by the University Hospital Foundation (Edmonton) and an unrestricted grant from DuPont Pharmaceuticals.

Footnotes

  • This article has been peer reviewed.

    Contributors: Dr. Bungard was involved in the conception and design of the study, analysis and interpretation of the data, the collection and assembly of data, drafting of the article and final approval of the article. Drs. Ghali and Tsuyuki were involved in the conception and design of the study, analysis and interpretation of the critical revision of the article for important intellectual content and final approval of the article. Dr. McAlister was involved in the conception and design of the study, analysis and interpretation of the data, statistical support, critical revision of the article for important intellectual content and final approval of the article. Dr. Shuaib was involved in the conception and design of the study, critical revision of the article for important intellectual content and final approval of the article. Drs. Buchan, Cave, Hamilton, Mitchell and Teo were involved in the acquisition and the analysis and interpretation of data and contributed to critical revision of the article for important intellectual content and final approval of the article.

    Competing interests: None declared for Drs. Ghali, McAlister, Cave, Hamilton and Mitchell. Dr. Bungard has received an unrestricted educational grant and honoraria for presentations from DuPont Pharmaceuticals. Dr. Buchan has received speaker fees from Hoffman-La Roche. Dr. Shuaib has been a paid consultant for and has received speaker fees and travel assistance from Boehringer Ingelheim, Sanofi, Pfizer and Astra Zeneca. Dr. Teo received speaker fees from DuPont Pharmaceuticals for a lecture on anticoagulation and atrial fibrillation. Dr. Tsuyuki has received several unrestricted travel grants and honoraria for presentations from DuPont Pharmaceuticals.

References

  1. 1.↵
    Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57.
    OpenUrlCrossRefPubMed
  2. 2.↵
    Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000; 160: 41-6.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation: analysis of pooled data from 3 randomized trials. Arch Intern Med 1997;157:1237-40.
    OpenUrlCrossRefPubMed
  4. 4.↵
    McCrory DC, Matchar DB, Samsa G, Sanders LL, Pritchett ELC. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med 1995;155:277-81.
    OpenUrlCrossRefPubMed
  5. 5.↵
    Chang HJ, Bell JR, Devoo DB, Kirk JW, Wasson JH. Physician variation in anticoagulating patients with atrial fibrillation. Arch Intern Med 1990;150:81-4.
    OpenUrl
PreviousNext
Back to top

In this issue

CMAJ
Vol. 165, Issue 3
7 Aug 2001
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Physicians' perceptions of the benefits and risks of warfarin for patients with nonvalvular atrial fibrillation
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Physicians' perceptions of the benefits and risks of warfarin for patients with nonvalvular atrial fibrillation
Tammy J. Bungard, William A. Ghali, Finlay A. McAlister, Alastair M. Buchan, Andrew J. Cave, Peter G. Hamilton, L. Brent Mitchell, Ashfaq Shuaib, Koon K. Teo, Ross T. Tsuyuki
CMAJ Aug 2001, 165 (3) 301-302;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Physicians' perceptions of the benefits and risks of warfarin for patients with nonvalvular atrial fibrillation
Tammy J. Bungard, William A. Ghali, Finlay A. McAlister, Alastair M. Buchan, Andrew J. Cave, Peter G. Hamilton, L. Brent Mitchell, Ashfaq Shuaib, Koon K. Teo, Ross T. Tsuyuki
CMAJ Aug 2001, 165 (3) 301-302;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Reasons for and consequences of oral anticoagulant underuse in atrial fibrillation with heart failure
  • Real world effectiveness of warfarin among ischemic stroke patients with atrial fibrillation: observational analysis from Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) study
  • Stroke prevention for patients with atrial fibrillation: improving but not perfect yet
  • The End of the Risk-Treatment Paradox?: A Rising Tide Lifts All Boats
  • Quality of Care for Atrial Fibrillation Among Patients Hospitalized for Heart Failure
  • Potentially Preventable Strokes in High-Risk Patients With Atrial Fibrillation Who Are Not Adequately Anticoagulated
  • Influence of decision aids on patient preferences for anticoagulant therapy: a randomized trial
  • Prognostic Implications of Warfarin Cessation After Major Trauma: A Population-Based Cohort Analysis
  • From knowledge to practice in chronic cardiovascular disease: a long and winding road
  • Ethnic Differences in Patient Perceptions of Atrial Fibrillation and Anticoagulation Therapy: The West Birmingham Atrial Fibrillation Project * Editorial Comment: The West Birmingham Atrial Fibrillation Project
  • Google Scholar

More in this TOC Section

  • Neonatal exposure to active pulmonary tuberculosis in a health care professional
  • How should abridged scientific articles be presented in journals? A survey of readers and authors
  • Predictive value of a self-reported history of varicella infection in determining immunity in adults
Show more Research letter

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire